Invesco Dynamic Biotechnology & Genome ETF (PBE) Holdings
PBE holdings summary
as of Oct 23, 2026- Holdings
- 31 positions listed
- Top 10 weight
- 49.5% of net assets
- Effective holdings
- 26 equal-weight equivalent
- Largest holding
- ILMN 5.97% Illumina, Inc.
- Annual turnover
- 72.8% of the portfolio traded
All PBE holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | ILMN | Illumina, Inc. | Healthcare | 5.97% | $25.7M | $39.64B | 49.0 |
| 2 | NTRA | Natera, Inc. | Healthcare | 5.80% | $25.0M | $56.71B | — |
| 3 | BIIB | Biogen Inc. | Healthcare | 5.53% | $23.8M | $34.37B | 41.3 |
| 4 | GILD | Gilead Sciences, Inc. | Healthcare | 5.29% | $22.8M | $193.67B | — |
| 5 | RPRX | Royalty Pharma plc | Healthcare | 5.15% | $22.2M | $35.22B | 32.4 |
| 6 | AMGN | Amgen Inc. | Healthcare | 4.89% | $21.1M | $233.82B | 26.9 |
| 7 | VRTX | Vertex Pharmaceuticals Incorporated | Healthcare | 4.72% | $20.3M | $126.66B | 28.9 |
| 8 | REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | 4.66% | $20.1M | $81.41B | 19.6 |
| 9 | MRNA | Moderna, Inc. | Healthcare | 4.02% | $17.3M | $87.04B | — |
| 10 | NVAX | Novavax, Inc. | Healthcare | 3.44% | $14.8M | $1.86B | — |
| 11 | HALO | Halozyme Therapeutics, Inc. | Healthcare | 3.13% | $13.5M | $13.83B | 35.6 |
| 12 | EXEL | Exelixis, Inc. | Healthcare | 3.13% | $13.5M | $15.42B | 19.6 |
| 13 | QGEN | Qiagen N.V. | Healthcare | 2.89% | $12.4M | $9.53B | 23.4 |
| 14 | SRPT | Sarepta Therapeutics, Inc. | Healthcare | 2.88% | $12.4M | $1.81B | — |
| 15 | UTHR | United Therapeutics Corporation | Healthcare | 2.86% | $12.3M | $22.87B | 19.1 |
| 16 | RGEN | Repligen Corporation | Healthcare | 2.70% | $11.6M | $11.14B | 240.3 |
| 17 | TGTX | TG Therapeutics, Inc. | Healthcare | 2.67% | $11.5M | $8.26B | 19.6 |
| 18 | VCEL | Vericel Corporation | Healthcare | 2.66% | $11.5M | $2.05B | 85.4 |
| 19 | VCYT | Veracyte, Inc. | Healthcare | 2.65% | $11.4M | $3.47B | 30.8 |
| 20 | PTGX | Protagonist Therapeutics, Inc. | Healthcare | 2.58% | $11.1M | $8.33B | 125.0 |
| 21 | LEGN | Legend Biotech Corporation | Healthcare | 2.54% | $10.9M | $3.59B | — |
| 22 | NBIX | Neurocrine Biosciences, Inc. | Healthcare | 2.52% | $10.8M | $13.79B | 19.9 |
| 23 | PTCT | PTC Therapeutics, Inc. | Healthcare | 2.42% | $10.4M | $4.94B | — |
| 24 | INCY | Incyte Corporation | Healthcare | 2.34% | $10.1M | $22.92B | 14.4 |
| 25 | COLL | Collegium Pharmaceutical, Inc. | Healthcare | 2.23% | $9.6M | $755.0M | 18.3 |
| 26 | BMRN | BioMarin Pharmaceutical Inc. | Healthcare | 2.21% | $9.5M | $10.58B | 147.8 |
| 27 | ARDX | Ardelyx, Inc. | Healthcare | 2.20% | $9.5M | $797.8M | — |
| 28 | ANAB | AnaptysBio, Inc. | Healthcare | 2.18% | $9.4M | $1.39B | — |
| 29 | BCRX | BioCryst Pharmaceuticals, Inc. | Healthcare | 2.17% | $9.3M | $1.99B | — |
| 30 | ACAD | ACADIA Pharmaceuticals Inc. | Healthcare | 1.89% | $8.1M | $3.29B | 8.6 |
| 31 | AGPXX | Invesco Short-Term Investments Trust Government & Agency Portfolio Institutional | Other | 0.04% | $180,992.92 | — | — |
Weights as a percentage of net assets. Value held = weight × net assets ($430.9M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
PBE sector breakdown
Sum of the weights of the holdings in each sector.
PBE top industries
PBE overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| IBB | iShares Biotechnology ETF | 43.2% | 25 of 234 | 0.46% |
| BIS | ProShares UltraShort Nasdaq Biotechnology | 40.5% | 17 of 104 | 0.96% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 39.8% | 27 of 245 | 0.18% |
| DIA | SPDR Dow Jones Industrial Average ETF | 4.9% | 1 of 30 | 0.16% |
| QQQ | Invesco QQQ ETF | 3.2% | 5 of 101 | 0.17% |
| VTI | Vanguard Total Stock Market ETF | 1.3% | 27 of 2,941 | 0.03% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the PBE portfolio
Invesco Dynamic Biotechnology & Genome ETF holds 31 positions. The ten largest make up 49.5% of the fund, so it behaves like a portfolio of about 26 equally weighted stocks. The biggest positions are Illumina, Inc. (5.97%), Natera, Inc. (5.80%), Biogen Inc. (5.53%), Gilead Sciences, Inc. (5.29%), Royalty Pharma plc (5.15%).
By sector, Healthcare is 100.3%, Other is 0.0%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 23, 2026; positions change as the fund rebalances.
Related: PBE chart, PBE performance, PBE dividends, PBE valuation, PBE overview.
PBE holdings FAQ
How many holdings does PBE have?
PBE holds 31 positions as of October 23, 2026.
What are the top 10 holdings of PBE?
The ten largest holdings are Illumina, Inc. (5.97%), Natera, Inc. (5.80%), Biogen Inc. (5.53%), Gilead Sciences, Inc. (5.29%), Royalty Pharma plc (5.15%), Amgen Inc. (4.89%), Vertex Pharmaceuticals Incorporated (4.72%), Regeneron Pharmaceuticals, Inc. (4.66%), Moderna, Inc. (4.02%), Novavax, Inc. (3.44%). Together they are 49.5% of the fund.
What percentage of PBE is Illumina, Inc.?
Illumina, Inc. is the largest holding at 5.97% of net assets, about $25.7M of the fund's $430.9M.
How concentrated is PBE?
The top 10 holdings are 49.5% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) PBE behaves like a portfolio of about 26 equally weighted stocks.